[Use of an immunomodulator (levamisole) in HbsAg positive patients].
The results of some clinical trials performed with levamisole on 12 HBsAg-positive subjects, including 5 patients with aggressive chronic hepatitis, (ACH) 2 patients with persistent chronic hepatitis (PCH) and 5 healthy carriers are reported. Levamisole was administered in 2.5 mg/Kg/day doses for three consecutive days. During treatment prothrombin activity normalized in ACH and PCH as well as transaminases, the latter starting from the 4th week, even though a two-fourfold increase of the starting values was observed in the first weeks of disease. HBsAg, anti-HBs titres and immunocomplexes values did not show any significant variations, but for 1 case, while some immunological parameters (E, EA rosettes) normalized in those cases showing base- values lower than the norm.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002908:Chronic Disease; D006509:Hepatitis B / Q000188:drug therapy* / Q000276:immunology; D006514:Hepatitis B Surface Antigens; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D011517:Prothrombin Time
D006514:Hepatitis B Surface Antigens; D007978:Levamisole; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Impiego di un immunomodulatore (levamisolo) in pazienti HBaAg positivi.